{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:08:00Z","timestamp":1783775280154,"version":"3.55.0"},"reference-count":28,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T00:00:00Z","timestamp":1403481600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:sec id=\"S0924270814000167_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the safety (primary objective) and efficacy (secondary objective) of (\u2212)-OSU6162 in Huntington\u2019s disease (HD).<\/jats:p><\/jats:sec><jats:sec id=\"S0924270814000167_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>In a double-blind, cross-over trial, patients with HD were randomly assigned to start treatment on either (\u2212)-OSU6162 or placebo. After 4 weeks, those patients who initially received active drug were switched to placebo for another 4 weeks, and vice versa. During the first week the (\u2212)-OSU6162 dose was 15 mg twice daily, during the second week 30 mg twice daily, and during the last 2 weeks 45 mg twice daily. Motor, cognitive, mental and social functions were rated by the clinical investigator or by self-assessment, using established rating scales.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270814000167_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Fifteen patients fulfilling inclusion and exclusion criteria completed the study. (\u2212)-OSU6162 was well tolerated by all patients and no adverse effects were observed. (\u2212)-OSU6162 treatment significantly improved the Short Form 36 Vitality score, mainly due to an improvement of the individual item \u2018worn-out\u2019 (VT3). In addition, an improvement of depressive symptoms was found using Beck Depression Inventory. In contrast to a general trend of improvement in several non-motor variables only small and non-significant differences between (\u2212)-OSU6162 and placebo were found regarding motor functions.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270814000167_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>(\u2212)-OSU6162 offers promise for the treatment of HD, as a drug with good tolerability, capable of improving the patients\u2019 experienced non-motor functions such as energy and mood and thus alleviating symptoms of great importance for their quality of life.<\/jats:p><\/jats:sec>","DOI":"10.1017\/neu.2014.16","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T13:59:28Z","timestamp":1403531968000},"page":"298-306","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":21,"title":["Tolerability and efficacy of the monoaminergic stabilizer (\u2212)-OSU6162 (PNU-96391A) in Huntington\u2019s disease: a double-blind cross-over study"],"prefix":"10.1017","volume":"26","author":[{"given":"Angelica","family":"Kloberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Karin Lena","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lizzie","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvid","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,6,23]]},"reference":[{"key":"S0924270814000167_ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204"},{"key":"S0924270814000167_ref25","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.102905"},{"key":"S0924270814000167_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-5215.2012.00678.x"},{"key":"S0924270814000167_ref26","doi-asserted-by":"crossref","unstructured":"Tolboom N , Berendse HW , Leysen JE et al. The dopamine stabilizer (\u2013)-OSU6162 occupies a subpopulation of striatal dopamine D2\/D3 receptors: an [11C]-raclopride PET study in healthy human subjects. 2014. Submitted to Neuropsychopharmacology, minor revision.","DOI":"10.1038\/npp.2014.195"},{"key":"S0924270814000167_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-011-0701-y"},{"key":"S0924270814000167_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60111-1"},{"key":"S0924270814000167_ref11","unstructured":"European Huntington\u2019s Disease Network: www.euro-hd.net"},{"key":"S0924270814000167_ref12","first-page":"271","volume-title":"Quantification of Neurologic Deficit","author":"Shoulson","year":"1989"},{"key":"S0924270814000167_ref9","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25362"},{"key":"S0924270814000167_ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2006.04985.x"},{"key":"S0924270814000167_ref10","first-page":"48","article-title":"Effects of the dopaminergic stabilizer pridopidine on motor symptoms in Huntington\u2019s disease: a meta-analysis","volume":"80","author":"Landwehrmeyer","year":"2011","journal-title":"Clin Genet"},{"key":"S0924270814000167_ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.7.1605"},{"key":"S0924270814000167_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.03.002"},{"key":"S0924270814000167_ref16","unstructured":"Website: www.alswh.org.au, ALSWH (Australian Longitudinal Study on Women\u2019s Health). Additional site information: For Researchers\/Data\/Data Dictionary Supplement\/ Section 2, Core Survey Dataset\/ 2.3 Health-related Quality of Life Variables, SF-36 (http:\/\/www.alswh.org.au\/for-researchers\/data\/data-dictionary-supplement)."},{"key":"S0924270814000167_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70233-2"},{"key":"S0924270814000167_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/31.1.140"},{"key":"S0924270814000167_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2012.04.021"},{"key":"S0924270814000167_ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-011-0704-8"},{"key":"S0924270814000167_ref20","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.157"},{"key":"S0924270814000167_ref27","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003262792"},{"key":"S0924270814000167_ref19","volume-title":"Nonparametric Statistical Methods","author":"Hollander","year":"1999"},{"key":"S0924270814000167_ref13","doi-asserted-by":"publisher","DOI":"10.1021\/jm00043a013"},{"key":"S0924270814000167_ref15","volume-title":"SF-36 Health Survey: manual and interpretation guide","author":"Ware","year":"1993"},{"key":"S0924270814000167_ref18","first-page":"463","volume-title":"Encyclopedia of Statistical Sciences, Volume 3","author":"Hodges","year":"1983"},{"key":"S0924270814000167_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-008-0038-3"},{"key":"S0924270814000167_ref24","unstructured":"Svensson KA , Falcone JF , Johansson AM et al. The actions of the dopamine stabilizer ACR16, but not (\u2013)-OSU6162, in behavioral and neurochemical assays are not dependent on the presence of functional D2 receptors. Society for Neuroscience Annual Meeting, 9\u201313 November 2009, San Diego."},{"key":"S0924270814000167_ref17","volume-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"key":"S0924270814000167_ref3","first-page":"545","article-title":"Tetrabenazine in the treatment of Huntington\u2019s disease","volume":"3","author":"Paleacu","year":"2007","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270814000167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T20:45:33Z","timestamp":1565556333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270814000167\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,23]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0924270814000167"],"URL":"https:\/\/doi.org\/10.1017\/neu.2014.16","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,23]]},"assertion":[{"value":"\u00a9 Scandinavian College of Neuropsychopharmacology 2014\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}